DGAT Inhibitors
1 drugsAbout DGAT
Diacylglycerol acyltransferases (DGATs) are enzymes catalyzing the final step in triglyceride synthesis, essential for energy storage and lipid metabolism.
DGAT's role in triglyceride production makes it a potential drug target for metabolic disorders, though there is currently no genetic evidence directly linking it to specific diseases.
One FDA-approved drug, VASCEPA, targets DGAT as a small molecule for metabolic indications, developed by AMARIN PHARMS.
Strategic Insights
ℹ️ How we calculate- White space opportunity in Endometrial Cancer with only 1 trials.
Top Drugs
AMARIN PHARMS is the only company with an approved DGAT-targeting drug.
Low competition suggests an opportunity for new entrants, but also indicates potential challenges in target validation.
Drug Modality Landscape
Modalities
Routes of Administration
Only one approved drug targets DGAT, using small molecule modality.
Explore alternative modalities like antibodies or peptides to differentiate from existing therapies.
Clinical Trials 38 trials
Completion by Phase
| Phase | Total | Completed | Failed | Active | Completion |
|---|---|---|---|---|---|
| Phase 1 | 11 | 10 | 0 | 1 | 100% |
| Phase 2 | 9 | 6 | 1 | 2 | 86% |
| Phase 3 | 10 | 4 | 1 | 5 | 80% |
| Phase 4 | 8 | 4 | 3 | 1 | 57% |
Top Sponsors
By Modality
Top Conditions
Top Drugs
Drug Approval Timeline (2012 - 2012)
VASCEPA was first approved in 2012 and remains the only approved drug.
The lack of recent approvals indicates potential saturation or challenges in developing new DGAT-targeting drugs.
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 1 companies competing
- • Market share by company
Full Drug Portfolio
- • All 1 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 1-drug timeline
- • First-of-modality markers
Clinical Trials Analysis
- • Competition: High (15 sponsors)
- • White space: 10 underexplored indications
- • Success rates by condition
Full summary • All drugs • Genetic evidence • Trials • Timeline
How We Calculate These Metrics
Target Attractiveness Score
A 0-100 score based on trial activity, sponsor diversity, and completion rates. Calculated from 29 clinical trials targeting DGAT.
Completion rate: Percentage of trials that reached their planned endpoint. Trials terminated early, withdrawn, or suspended are not counted—these often indicate safety issues, lack of efficacy, or strategic pivots.
- Highly Attractive (80+): High trial activity, many sponsors, strong completion rates
- Attractive (60-79): Good trial activity and validation
- Moderate (40-59): Moderate interest from sponsors
- Low (under 40): Limited trial activity or validation concerns
Strategic Insights
Auto-generated insights based on trial analytics including competition intensity, white space opportunities, modality shifts, and failure patterns. We analyze trial sponsors, phases, indications, and outcomes.
Risk Signals
- High Competition: Many sponsors competing for this target (may reduce market opportunity)
- High Failure Risk: Low trial completion rates suggest development challenges
- Low Validation: Limited trial activity or poor outcomes indicate uncertain viability
- White Space Available: Underexplored indications present opportunities